Published in Brain Behav Immun on January 01, 2005
Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry (2008) 1.80
Immune suppression and immune activation in depression. Brain Behav Immun (2010) 1.48
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry (2012) 1.41
Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav Immun (2008) 1.30
High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci (2007) 1.03
Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS One (2012) 0.88
IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res (2010) 0.88
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol (2008) 0.88
Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys. AIDS (2009) 0.86
Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology (2012) 0.84
Mind and body: how the health of the body impacts on neuropsychiatry. Front Pharmacol (2013) 0.82
C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression. J Affect Disord (2014) 0.80
The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. Brain Behav Immun (2005) 0.80
Depression and antiviral response to interferon-based therapy for hepatitis C virus infection. Hepatology (2011) 0.79
Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices. Gen Hosp Psychiatry (2009) 0.79
Hepatitis C, depressive symptoms, viral load, and therapy: interactions and reactions. Brain Behav Immun (2005) 0.78
Pathogen-Host Defense in the Evolution of Depression: Insights into Epidemiology, Genetics, Bioregional Differences and Female Preponderance. Neuropsychopharmacology (2016) 0.78
Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. Curr Neuropharmacol (2015) 0.76
A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders. Curr Neuropharmacol (2016) 0.76
Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism. Pharmaceuticals (Basel) (2015) 0.75
Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review. Open Med (2009) 0.75
The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients. Gastroenterol Hepatol (N Y) (2007) 0.75
Comparison of the prevalence of psychiatric co-morbidities in hepatitis C patients and hepatitis B patients in Saudi Arabia. Saudi J Gastroenterol (2013) 0.75
Use of fMRI to predict psychiatric adverse effects of interferon treatment for Hepatitis C - preliminary report. Neuropsychiatr Dis Treat (2007) 0.75
Quantifying serotonin transporters by PET with [11C]-DASB before and after interferon-α treatment. Synapse (2014) 0.75
Evaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis C treatment completion rates at a veterans affairs medical center. Hepat Res Treat (2013) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol (2005) 8.49
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA (2008) 6.60
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci (2012) 4.71
Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 4.65
The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry (2007) 4.51
The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry (2005) 4.45
The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology (2008) 4.35
When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry (2003) 3.68
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 3.33
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol (2008) 3.30
Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry (2004) 3.26
Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology (2002) 3.24
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry (2002) 3.05
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Early life programming and neurodevelopmental disorders. Biol Psychiatry (2010) 2.93
Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry (2004) 2.83
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81
Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun (2006) 2.78
Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 2.75
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (2013) 2.68
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (2003) 2.48
Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring. Neuropsychopharmacology (2005) 2.35
Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology (2011) 2.31
Reduced glucocorticoid receptors: consequence or cause of depression? Trends Endocrinol Metab (2006) 2.26
Neurobiological and psychiatric consequences of child abuse and neglect. Dev Psychobiol (2010) 2.17
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University. Depress Anxiety (2008) 2.16
Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry (2003) 2.13
Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther (2011) 2.12
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry (2003) 2.05
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology (2004) 2.03
Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry (2008) 1.96
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs (2005) 1.93
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry (2003) 1.92
Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry (2003) 1.90
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry (2005) 1.80
Long-term behavioural and molecular alterations associated with maternal separation in rats. Eur J Neurosci (2007) 1.79
The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology (2011) 1.74
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: a multiple regression analysis. Depress Anxiety (2002) 1.72
The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma. Biol Psychiatry (2007) 1.71
Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry (2008) 1.70
Alterations in diurnal cortisol rhythm and acoustic startle response in nonhuman primates with adverse rearing. Biol Psychiatry (2005) 1.65
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry (2002) 1.65
Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology (2007) 1.63
Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol (2005) 1.63
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Is depression an inflammatory disorder? Curr Psychiatry Rep (2011) 1.60
Hypercortisolemia and depression. Psychosom Med (2005) 1.60
Long-term adaptations in glucocorticoid receptor and mineralocorticoid receptor mRNA and negative feedback on the hypothalamo-pituitary-adrenal axis following neonatal maternal separation. Biol Psychiatry (2004) 1.59
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology (2006) 1.59
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry (2005) 1.58
Are plasma citrulline and glutamine biomarkers of intestinal absorptive function in patients with short bowel syndrome? JPEN J Parenter Enteral Nutr (2007) 1.55